Literature DB >> 3067486

Immunosuppressive effects of blood transfusion in anaesthesia and surgery.

M Salo1.   

Abstract

The immunosuppressive effects of blood transfusion at surgical operations become manifest as enhanced graft survival, increased cancer recurrence and decreased patient survival, and increased susceptibility to postoperative infections. Blood transfusion in transplant recipients no longer offers this advantage when cyclosporine A is used. The deleterious effects of blood transfusion on the prognosis of some cancers found in the statistical analyses of retrospective studies are considered to be of increasing clinical importance. Therefore, unnecessary blood transfusions should be avoided and special attention directed to the use of autologous blood. Leucocyte-free red blood concentrates are the least immunosuppressive homologous blood preparations. Conventional red blood cell concentrates may also be used in cancer patients until ongoing prospective randomized studies confirm that there is a true association between the use of homologous blood and increased recurrence of cancer.

Entities:  

Mesh:

Year:  1988        PMID: 3067486     DOI: 10.1111/j.1399-6576.1988.tb02839.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand Suppl        ISSN: 0515-2720


  4 in total

1.  Cytokine and coagulation characteristics of retrieved blood after arthroplasty.

Authors:  M Kristiansson; M Soop; L Saraste; K G Sundqvist; A M Suontaka; M Blomback
Journal:  Intensive Care Med       Date:  1995-12       Impact factor: 17.440

Review 2.  Blood loss in total hip replacement. A retrospective study.

Authors:  P A Flordal; G Neander
Journal:  Arch Orthop Trauma Surg       Date:  1991       Impact factor: 3.067

3.  Assessment of immunoglobulins after hip replacement.

Authors:  M Shtarbova; S Klein
Journal:  Int Orthop       Date:  1995       Impact factor: 3.075

4.  Debate: transfusing to normal haemoglobin levels will not improve outcome.

Authors:  G Alvarez; P C Hébert; S Szick
Journal:  Crit Care       Date:  2001-03-08       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.